Vimizim launch price $380000 2014?

Yes—when Sanofi launched Vimizim (alglucosidase‑alpha) for Pompe disease in 2014, the U.S. launch price was roughly $380,000 per year (about $380 k for the first treatment course). Prices have fluctuated since then and can differ by payer, region, and reimbursement negotiations, but $380 k was the approximate starting point at launch.